BioMarin's Amicus Bet: A New Growth Engine Takes Shape
First quarter results confirm integration is on track, as pipeline readouts loom.
BMRN · Earnings Call · 2026-05-04
Closing the Amicus Deal
BioMarin entered a new chapter last week with the close of its Amicus acquisition, bringing Galafold (Fabry) and Pombility/Opfolda (Pompe) into the fold. As CEO Alexander Hardy said, “I am so pleased that we completed the Amicus acquisition last week, starting a new and exciting chapter for BioMarin Pharmaceutical Inc. with the addition of two innovative therapies.” — Alexander Hardy, CEO · 2026-05-04 The integration is already being reflected in guidance. CFO Brian Mueller noted, “We are raising Enzyme Therapies revenue guidance to a range of $2.725 billion to $2.775 billion for the full year 2026 inclusive of meaningful contributions from Galafold and Pombility and Opfolda, resulting in approximately 30% growth at the midpoint.” — Brian Mueller, CFO · 2026-05-04 This lifts total revenue guidance to $3.825–$3.925B, a 20% YoY growth at the midpoint. The Galafold and Pombility/Opfolda contributions are expected to be substantial, with the company planning to share more on peak revenue and synergies next quarter.
Q1: Order Timing Masks Demand
Q1 total revenue came in at $766M, up only 3% YoY, but management emphasized that underlying patient demand is robust. The disconnect is entirely due to order timing, as Brian explained: “It is important to emphasize that the disconnect between the underlying patient demand growth and reported revenues is entirely order timing.” — Brian Mueller, CFO · 2026-05-04 This echoes the theme from the previous quarter, when order timing also distorted results. The company expects more than 55% of 2026 revenues to be recognized in the second half.
The patient demand story is particularly strong for Voxzogo, where new patient starts increased more than 20% YoY, with over half of U.S. starts coming from children under two. Cristin Hubbard highlighted, “Over half of new patient starts were from children under age two, a greater proportion compared to last quarter.” — Cristin Hubbard, Head of Commercial or Commercial Lead · 2026-05-04 This focus on early treatment is central to the strategy.
Pipeline Catalysts Abound
R&D momentum is building with several near-term catalysts. Hypochondroplasia data for Voxzogo is expected in Q2, and enrollment in the BMN-333 phase 2/3 study is underway. Greg Friberg noted, “We are also pleased to share that enrollment is underway in our global registrational-enabling phase 2/3 study.” — Gregory Friberg, Head of R&D or Medical Affairs · 2026-05-04 The company is also awaiting pivotal data for BMN-401 in ENPP1 deficiency.
The hypochondroplasia opportunity is significant, with a total addressable population of 14,000 patients globally. Management is confident in the science, and the rapid enrollment suggests strong interest.
Financial Health and Valuation
Despite the Q1 earnings dip (non-GAAP EPS of $0.76, impacted by a $31M charge), the balance sheet is strong. Effective net cash stands at $4.6B, up 108% YoY, giving ample firepower for further BD or investments. The stock has rebounded recently, up ~22% over the past 90 days, but remains well off its 2015 peak.
The acquisition is expected to be modestly dilutive in 2026 but accretive within 12 months and substantially accretive in 2027. As Mueller said, “we are reaffirming our previous expectation that, while as you saw in the EPS guide today, the Amicus acquisition is slightly dilutive to calendar 2026, it will be accretive for the first twelve months following closing and then substantially accretive beginning full year 2027.” — Brian Mueller, CFO · 2026-05-04
Total Revenue for Q1 2026 was $766M, with the company guiding to $3.825-$3.925B for the year.
The competitive landscape remains a watchpoint, with the ITC decision on Voxzogo expected in August. Alexander Hardy commented on the proceedings, “We expect to receive a decision on whether Ascendis' product infringes our patent on or about August 21.” — Alexander Hardy, CEO · 2026-05-04 This could have significant implications for the achondroplasia market.
Overall, BioMarin is at an inflection point, with the integration of Amicus setting the stage for accelerated growth. The coming quarters will be pivotal, with pipeline readouts and commercial execution under scrutiny.